Count the outcome before interpreting the result
Incidence counts new diagnoses in a population over a period. Prostate-cancer mortality counts deaths attributed to that cancer; all-cause mortality counts deaths from any cause. These are different outcomes and may involve different denominators and observation periods.
As a reading example, two groups could have similar numbers of new diagnoses while differing in deaths attributed to prostate cancer. That would not be a contradiction. Nor would a cancer-specific death rate tell us the probability of death for every person already diagnosed.
Stage, grade and progression describe different things
Stage describes the extent of cancer in the body. Grade describes how abnormal cells and tissue look under a microscope. Progression concerns a change in disease over follow-up, with definitions that differ between studies. Neither stage nor grade is a number to infer from smoking or urinary changes.
The 2014 report judged the evidence suggestive for more advanced stage, poorer differentiation and higher progression risk among smokers with prostate cancer. “Suggestive” is part of the conclusion, rather than a claim that every tumour behaves that way or that smoking alone explains it.
A real review kept mortality and incidence separate
A 2014 systematic review combined 51 articles from prospective cohorts. It designated prostate-cancer mortality as the primary outcome and incidence as secondary. Current smoking was associated with higher cancer-specific mortality, while the incidence findings varied substantially across studies and study eras.
That variation matters: diagnosis patterns and differences between comparison groups can affect the count of detected cancers. The review’s incidence result cannot be turned into a protective effect of smoking. Combining many observational studies also does not make the comparison a randomized experiment or establish the cause of a particular outcome.
Read the finding without turning it into a personal forecast
Ask whether a report follows a general population or people already diagnosed, and whether it measures new diagnoses, progression or cancer-specific deaths. Current, former and never smoking are distinct groups; a favourable former-smoking comparison does not provide a personal recovery deadline.
For individual prostate questions, discuss the context with a qualified primary-care or urology clinician. In the UK, NHS local stop-smoking services provide a separate support route; elsewhere use corresponding local care. This page does not interpret PSA, choose screening or biopsies, alter cancer treatment or estimate survival.
Sources
The central claims on this page were checked against the sources below.
- US Surgeon General / CDC, NCBI Bookshelf: 2014 Surgeon General cancer conclusions, prostate row
Sources checked: 2026-10-10
- CDC: 2018 MMWR prostate incidence and mortality discussion
Sources checked: 2026-10-10
- Islami et al., European Urology: 2014 systematic review of tobacco and prostate mortality and incidence
Sources checked: 2026-10-10
- NCI: Definition of stage
Sources checked: 2026-10-10
- NCI: Definition of grade
Sources checked: 2026-10-10
- NHS: NHS local stop smoking support
Sources checked: 2026-10-10
Adult population education. No urinary-symptom diagnosis, PSA interpretation, personal staging or grading, screening or biopsy choice, treatment change, survival probability or guaranteed benefit after stopping smoking.